We evaluated an enzyme-linked immunosorbent assay (ELISA) for embryonic ζ-globin chains as a routine screening test for (--SEA) α-thalassemia deletion (SEA deletion). A total of 174 consecutive patient samples with a request for Hb analysis were recruited. The ELISA method was evaluated against a polymerase chain reaction (PCR)-based technique that was taken as the standard. Among 56 simple carriers of SEA deletion diagnosed by PCR and 112 subjects without the SEA deletion, the sensitivity and specificity of the ELISA method was 89.3–96.4 and 98.2–100%, respectively, depending on the cutoff value for optical density that was adopted. The ELISA method was able to detect both subjects with SEA deletion and concurrent β-thalassemia trait in this series, but only 1 out of 4 patients (25%) with Hb H disease. We speculate that incomplete lysis of hypochromic microcytic red cells together with the low red cell count in Hb H disease might account for the false-negative results. We showed that the ELISA method for embryonic ζ-chains was a sensitive method of screening for SEA deletion carriers at our locality, and should be easily adopted in a routine diagnostic laboratory. The method was rapid and also amendable to automation. In areas with a high prevalence of α-thalassemia, improved detection of SEA deletion carriers would ultimately facilitate the identification of pregnancies at risk of hydrops fetalis and its prevention through prenatal diagnosis.

Keywords:
ELISA, Embryonic ζ-globin chains, SEA deletion, Thalassemia screening, α-Thalassemia
1.
Lau YL, Chan LC, Chan AY-Y, Ha SY, Yeung CY, Waye JS, Chui DHK: Prevalence and genotypes of α- and β-thalassemia carriers in Hong Kong – Implications for population screening. N Engl J Med 1997;336:1298–1301.
2.
Chui DHK, Waye JS: Hydrops fetalis caused by α-thalassemia: An emerging health care problem. Blood 1998;91:2213–2222.
3.
Ma ESK, Chan AYY, Ha SY, Chan GCF, Lau YL, Chan LC: Screening for (--SEA) α-globin gene deletion in β-thalassemia carriers and prevention of hydrops fetalis. Haematologica 2000;85:991–993.
4.
Chang J-G, Lee L-S, Lin C-P, Chen P-H, Chen C-P: Rapid diagnosis of α-thalassemia-1 of Southeast Asia type and hydrops fetalis by polymerase chain reaction. Blood 1991;78:853–854.
5.
Chan AYY, So CKC, Chan LC: Comparison of the Hb H inclusion test and a PCR test in routine screening for α thalassaemia in Hong Kong. J Clin Pathol 1996;49:411–413.
6.
Chui DHK, Wong SC, Chung S-W, Patterson M, Bhargava S, Poon M-C: Embryonic ζ-globin chains in adults: A marker for α-thalassemia-1 haplotype due to a >17.5-kb deletion. N Engl J Med 1986;314:76–79.
7.
Luo H-Y, Clarke BJ, Gauldie J, Patterson M, Liao S-K, Chui DHK: A novel monoclonal antibody based diagnostic test for α-thalassemia-1 carriers due to the (--SEA) deletion. Blood 1988;72:1589–1594.
8.
Tang W, Luo H-Y, Albitar M, Patterson M, Eng B, Waye JS, Liebhaber SA, Higgs DR, Chui DHK: Human embryonic ζ-globin chain expression in deletional α-thalassemias. Blood 1992;80:517–522.
9.
Harada F, Ireland JH, Hsia YE, Chui DHK: Anti-ζ antibody screening for α-thalassemia using dried filter paper blood. Biochem Med Metab Biol 1994;51:80–84.
10.
Luo H-Y, Deisseroth AB, Chui DHK: Human embryonic ζ-globin gene expression in mouse-human hybrid erythroid cell lines. Blood 1995;86:1212–1217.
11.
Tang W, Luo H-Y, Eng B, Waye JS, Chui DHK: Immunocytological test to detect adult carriers of (--SEA) deletional α-thalassaemia. Lancet 1993;342:1145–1147.
12.
Chan LC, So JCC, Chui DHK: Comparison of haemoglobin H inclusion bodies with embryonic ζ globin in screening for α thalassaemia. J Clin Pathol 1995;48:861–864.
13.
Simkins RA, Than K-A, Schapiro B, Choi ES, Daoust PR: Correlation of ζ-globin ELISA with PCR for (--SEA) deletion and clinical diagnosis for α-thal-1 trait. Ann NY Acad Sci 1998;850:429–431.
14.
Lafferty J, Crowther M, Waye JS, Chui DHK: A reliable screening test to identify adult carriers of the (--SEA) alpha0-thalassemia deletion. Detection of embryonic zeta-globin chains by enzyme-linked immunosorbent assay. Am J Clin Pathol 2000;114:927–931.
15.
Ausavarungnirun R, Winichagoon P, Fucharoen S, Epstein N, Simkins R: Detection of ζ-globin chains in the cord blood by ELISA (enzyme-linked immunosorbent assay): Rapid screening for α-thalassemia 1 (Southeast Asian type). Am J Hematol 1998;57:283–286.
16.
Bowden DK, Vickers MA, Higgs DR: A PCR-based strategy to detect the common severe determinants of α thalassaemia. Br J Haematol 1992;81:104–108.
17.
Oron-Karni V, Filon D, Oppenheim A, Rund D: Rapid detection of the common Mediterranean α-globin deletions/rearrangements using PCR. Am J Hematol 1998;58:306–310.
18.
Smetanina NS, Huisman THJ: Detection of α-thalassemia-2 (-3.7 kb) and its corresponding triplication ααα (anti-3.7 kb) by PCR: An improved technical change. Am J Hematol 1996;53:202–203.
19.
Higgs DR, Bowden DK: Clinical and laboratory features of the α-thalassemia syndromes; in Steinberg MH, Forget BG, Higgs DR, Nagel RL (eds): Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge, Cambridge University Press, 2001, pp 431–469.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.